Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

@article{Wolleschak2014ClinicallyRD,
  title={Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.},
  author={Denise Wolleschak and Thomas Sebastian Mack and Florian Perner and Stephanie A. Frey and Tina M. Schnoeder and Marko Wagner and Christine H{\"o}ding and Marina C. Pils and Andreas Parkner and Stefanie Kliche and Burkhart Schraven and Katrin Hebel and Monika C Brunner-Weinzierl and Satish Ranjan and Berend Isermann and Daniel B. Lipka and Thomas Fischer and Florian H Heidel},
  journal={Haematologica},
  year={2014},
  volume={99 6},
  pages={
          e90-3
        }
}
The vast majority of acute myeloid leukemia (AML) patients harboring an FLT3-ITD mutation experience relapse within a short period of time after discontinuation of chemotherapy. 1 Treatment options include experimental trials using FLT3-tyrosine kinase inhibitors (TKI) or allo-geneic stem cell transplantation (alloSCT). Inhibitors that are currently being investigated in advanced clinical trials with promising clinical responses include midostaurin (PKC412) and quizartinib (AC220). Resistance… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Similar Papers

Loading similar papers…